Conditions: Healthy Volunteers
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 24
Healthy volunteers: yes

Brief summary:
The purpose of this study is to determine whether concentrations of the study drug (evacetrapib) in the blood stream is the same or is different when the person is also taking gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may have occurred will also be collected. This study will last approximately 36 days.

Detailed description:

Arms:
arm 1: Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1 arm 2: Oral doses of 130 mg evacetrapib once a day (QD) for 10 days (Day 2 through Day 12) arm 3: Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.

Interventions: intervention 1: Evacetrapib intervention 2: Gemfibrozil
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: